Drug Profile
Research programme: bifunctional short hairpin cancer therapeutics - Gradalis/Mary Crowley Research Center
Alternative Names: pbi-shPDX-1 LP; pbi-shRNA K-ras LPLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Gradalis; Mary Crowley Cancer Research Center
- Class Lipids; Small interfering RNA
- Mechanism of Action Pancreatic and duodenal homeobox 1 protein inhibitors; RNA interference; Stathmin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Intratumoural, Injection)
- 06 Mar 2012 Preclinical development is ongoing in USA